NASDAQ:AGIO Agios Pharmaceuticals (AGIO) Stock Price, News & Analysis $48.05 -0.45 (-0.93%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$47.77▼$49.2950-Day Range$31.50▼$49.7252-Week Range$19.80▼$50.35Volume333,773 shsAverage Volume796,395 shsMarket Capitalization$2.73 billionP/E RatioN/ADividend YieldN/APrice Target$50.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Agios Pharmaceuticals alerts: Email Address Agios Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside5.4% Upside$50.67 Price TargetShort InterestBearish5.76% of Float Sold ShortDividend StrengthN/ASustainability-0.80Upright™ Environmental ScoreNews Sentiment0.89Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.15) to ($5.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.31 out of 5 starsMedical Sector782nd out of 936 stocksPharmaceutical Preparations Industry361st out of 436 stocks 1.3 Analyst's Opinion Consensus RatingAgios Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAgios Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Agios Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.76% of the float of Agios Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAgios Pharmaceuticals has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Agios Pharmaceuticals has recently increased by 1.92%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAgios Pharmaceuticals does not currently pay a dividend.Dividend GrowthAgios Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAgios Pharmaceuticals has received a 75.34% net impact score from Upright. Agios Pharmaceuticals seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Creating knowledge". The positive contribution in the "Physical diseases" impact category is mostly driven by its "Preclinical research services for physical health", "Clinical research services for cancer", and "Clinical research services for metabolic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Agios Pharmaceuticals is -0.80. Previous Next 2.7 News and Social Media Coverage News SentimentAgios Pharmaceuticals has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Agios Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for AGIO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Agios Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Agios Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.93% of the stock of Agios Pharmaceuticals is held by insiders.Read more about Agios Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Agios Pharmaceuticals are expected to decrease in the coming year, from ($2.15) to ($5.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agios Pharmaceuticals is -7.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agios Pharmaceuticals is -7.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAgios Pharmaceuticals has a P/B Ratio of 3.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Agios Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About Agios Pharmaceuticals Stock (NASDAQ:AGIO)Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Read More AGIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AGIO Stock News HeadlinesJuly 26 at 7:30 AM | americanbankingnews.comAgios Pharmaceuticals, Inc. Forecasted to Earn Q2 2024 Earnings of ($1.68) Per Share (NASDAQ:AGIO)July 25 at 8:53 AM | benzinga.comAgios Pharmaceuticals (NASDAQ:AGIO) Stock, Short Interest ReportJuly 26, 2024 | Monument Traders Alliance (Ad)This student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... In fact, it just detected a move happening this MONDAY.July 25 at 5:12 AM | americanbankingnews.comAgios Pharmaceuticals (AGIO) Scheduled to Post Earnings on ThursdayJuly 24 at 7:50 PM | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Repare Therapeutics (RPTX)July 24 at 7:50 PM | finance.yahoo.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Has Found A Path To ProfitabilityJuly 18, 2024 | globenewswire.comAgios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024June 12, 2024 | seekingalpha.comAgios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising PipelineJuly 26, 2024 | Monument Traders Alliance (Ad)This student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... In fact, it just detected a move happening this MONDAY.June 3, 2024 | reuters.comAgios Pharmaceuticals' blood disorder drug succeeds in late-stage studyJune 3, 2024 | globenewswire.comAgios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-ThalassemiaMay 30, 2024 | globenewswire.comAgios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024May 28, 2024 | msn.comRoyalty Pharma Flat on Buying into AgiosMay 28, 2024 | finance.yahoo.comAgios cashes in on cancer drug again with $905M Royalty Pharma dealMay 28, 2024 | msn.comAgios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break OutMay 28, 2024 | finance.yahoo.comAgios Breaks Out On 'Buffed Up' Financials After Inking Massive Brain Cancer DealMay 28, 2024 | finanznachrichten.deRoyalty Pharma plc: Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 MillionMay 28, 2024 | markets.businessinsider.comAgios Pharma Stock Climbs On Royalty Pharma's Deal To Buy Royalty Stake In VorasidenibSee More Headlines Receive AGIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/26/2024Next Earnings (Confirmed)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AGIO CUSIPN/A CIK1439222 Webwww.agios.com Phone(617) 649-8600FaxN/AEmployees383Year FoundedN/APrice Target and Rating Average Stock Price Target$50.67 High Stock Price Target$53.00 Low Stock Price Target$46.00 Potential Upside/Downside+5.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($6.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-352,090,000.00 Net Margins-1,199.26% Pretax Margin-1,199.26% Return on Equity-41.41% Return on Assets-36.36% Debt Debt-to-Equity RatioN/A Current Ratio12.84 Quick Ratio12.39 Sales & Book Value Annual Sales$26.82 million Price / Sales101.71 Cash FlowN/A Price / Cash FlowN/A Book Value$14.51 per share Price / Book3.31Miscellaneous Outstanding Shares56,770,000Free Float53,974,000Market Cap$2.73 billion OptionableOptionable Beta0.79 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Brian M. Goff M.B.A. (Age 55)CEO & Director Comp: $1.23MMs. Cecilia Jones (Age 49)Chief Financial Officer Comp: $403.36kMr. James William Burns (Age 46)Corporate Secretary & Chief Legal Officer Comp: $660.33kDr. Sarah Gheuens M.D. (Age 44)Ph.D., Chief Medical Officer and Head of Research & Development Comp: $769.2kDr. Lewis Clayton Cantley Ph.D. (Age 75)Co-Founder & Member of Scientific Advisory Board Comp: $50kDr. Tak Wah Mak D.Sc. (Age 78)FRSC, Ph.D., Co-Founder & Member of Scientific Advisory Board Dr. Craig B. Thompson M.D. (Age 71)Co-Founder & Chairman of Scientific Advisory Board Dr. Shin-San Su Ph.D. (Age 68)Co-Founder & Member of Scientific Advisory Board Mr. T. J. Washburn Jr. (Age 43)Principal Accounting Officer Dr. Clive Patience Ph.D. (Age 60)Chief Technical Operations Officer More ExecutivesKey CompetitorsCatalentNYSE:CTLTRoivant SciencesNASDAQ:ROIVIntra-Cellular TherapiesNASDAQ:ITCIAscendis Pharma A/SNASDAQ:ASNDCerevel TherapeuticsNASDAQ:CEREView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 27,193 shares on 7/26/2024Ownership: 0.393%Northcape Wealth Management LLCBought 5,670 shares on 7/25/2024Ownership: 0.010%Assenagon Asset Management S.A.Sold 319,821 shares on 7/18/2024Ownership: 0.238%Oak Ridge Investments LLCSold 4,807 shares on 7/17/2024Ownership: 0.062%Harbor Capital Advisors Inc.Bought 13,494 shares on 7/9/2024Ownership: 0.058%View All Insider TransactionsView All Institutional Transactions AGIO Stock Analysis - Frequently Asked Questions How have AGIO shares performed this year? Agios Pharmaceuticals' stock was trading at $22.27 at the beginning of 2024. Since then, AGIO stock has increased by 115.8% and is now trading at $48.05. View the best growth stocks for 2024 here. How were Agios Pharmaceuticals' earnings last quarter? Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) issued its quarterly earnings results on Thursday, May, 2nd. The biopharmaceutical company reported ($1.45) EPS for the quarter, topping analysts' consensus estimates of ($1.65) by $0.20. The business's revenue was up 46.0% on a year-over-year basis. What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO? 11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are Agios Pharmaceuticals' major shareholders? Agios Pharmaceuticals' top institutional shareholders include Bank of New York Mellon Corp (0.39%), Assenagon Asset Management S.A. (0.24%), Oak Ridge Investments LLC (0.06%) and Harbor Capital Advisors Inc. (0.06%). Insiders that own company stock include Jacqualyn A Fouse, Brian Goff, James William Burns, Sarah Gheuens, Cecilia Jones, Kaye I Foster-Cheek, Tsveta Milanova and Theodore James Jr Washburn. View institutional ownership trends. How do I buy shares of Agios Pharmaceuticals? Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Agios Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE) and Vertex Pharmaceuticals (VRTX). This page (NASDAQ:AGIO) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agios Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AGIO Stock Alerts